Low-dose Aldesleukin Slows ALS Progression, Extends Survival: Trial
A low dose of aldesleukin, an immunotherapy approved for certain cancers, slowed disease progression and significantly improved survival in people…
Articles by Margarida Maia, PhD
DNL343 Well-tolerated by ALS Patients, Interim Data Show
DNL343, an investigational oral small molecule developed by Denali Therapeutics, can extensively enter the brain and reduce the cellular…
NP001 May Slow ALS Progression by Limiting ‘Leaks’ of Gut Bacteria
Neuvivo’s NP001 (sodium chlorite) may help slow the progression of amyotrophic lateral sclerosis (ALS) by taming the systemic inflammation…
FightMND Supports ALS Research on Inflammasome Blocker RRx-001
EpicentRx has been awarded funding from FightMND to study how well RRx-001, its lead small molecule, may protect…
First Patients Dosed in Eye Study of Tracer for ALS Diagnosis
The first patients have been dosed in a Phase 1/2a clinical study that’s testing AMDXP-2011P for its ability to trace…
App Can Help Monitor ALS Progression in Patients From Home
Using a digital tool to assess disease severity remotely is feasible for people with amyotrophic lateral sclerosis (ALS) and…
Stem Cell-based Therapy to Produce GDNF Found Safe in Human Trial
Stem cells engineered to mature into nerve-supporting cells that produce GDNF — a key factor for motor neuron survival —…
ALS Patients Have Higher Lead Levels in Blood, Review Study Finds
People with amyotrophic lateral sclerosis (ALS) have significantly higher blood levels of lead, a toxic heavy metal, than those…
Pasithea Receives Funding to Develop Antibodies for ALS
Pasithea Therapeutics has gained access to AU$1 million (about $694,000) to further its research into anti-integrin antibodies as potential…
AI Finds New Potential Targets for ALS Treatment in Patient Data
PandaOmics, an artificial intelligence (AI) platform that looks at vast amounts of data to find “druggable” molecules, has identified…